Kercheville Advisors LLC Makes New $470,000 Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Kercheville Advisors LLC purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 19,450 shares of the company’s stock, valued at approximately $470,000.

Other hedge funds have also bought and sold shares of the company. The Manufacturers Life Insurance Company grew its holdings in Hims & Hers Health by 44.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 116,477 shares of the company’s stock valued at $2,352,000 after purchasing an additional 36,081 shares during the last quarter. Creative Planning bought a new position in Hims & Hers Health during the 2nd quarter valued at about $443,000. Sanctuary Advisors LLC bought a new position in Hims & Hers Health during the 2nd quarter valued at about $415,000. Diversified Trust Co bought a new position in Hims & Hers Health during the 3rd quarter valued at about $233,000. Finally, Strategic Wealth Partners Ltd. grew its holdings in Hims & Hers Health by 57.6% during the 3rd quarter. Strategic Wealth Partners Ltd. now owns 109,199 shares of the company’s stock valued at $2,011,000 after purchasing an additional 39,896 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on HIMS shares. Needham & Company LLC upped their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 6th. Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. Deutsche Bank Aktiengesellschaft upped their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. TD Cowen restated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, Morgan Stanley assumed coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 target price on the stock. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $25.13.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 4,153 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $35.30, for a total value of $146,600.90. Following the completion of the transaction, the insider now owns 161,497 shares of the company’s stock, valued at approximately $5,700,844.10. This trade represents a 2.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the firm’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $38.92, for a total transaction of $450,732.52. Following the completion of the transaction, the chief financial officer now directly owns 112,933 shares of the company’s stock, valued at approximately $4,395,352.36. This represents a 9.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,167,913 shares of company stock valued at $34,303,787 over the last 90 days. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $42.12 on Thursday. Hims & Hers Health, Inc. has a fifty-two week low of $8.58 and a fifty-two week high of $44.43. The company has a 50 day moving average price of $29.82 and a 200-day moving average price of $23.00. The stock has a market capitalization of $9.20 billion, a PE ratio of 95.72 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the prior year, the company posted ($0.04) earnings per share. Hims & Hers Health’s revenue for the quarter was up 77.1% compared to the same quarter last year. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.